Japan Drug Makers See Need To Catch Up In Biotechs
This article was originally published in PharmAsia News
Japanese drug makers are attempting to catch up to their major rivals abroad by stepping up efforts to bring antibody and other bioengineered pharmaceuticals to market. U.S. and European companies have dominated the market for biotech drugs, but Takeda and other drug makers hope to close the gap. Takeda has applications pending in Japan for an antibody drug, while Eisai and Chugai market theirs, but they and other Japanese drug makers continue to lag. The smaller share of the world market usually means the drug makers also spend less on research. (Click here for more - a subscription may be required
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.